Phase 1 N=32 Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates
Sepsis
Primary: Piperacillin Pharmacokinetics (PK) — 0.0799 L/hr/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Effect of Vitamin D Replacement on Insulin Sensitivity
Insulin Sensitivity
Primary: M Value (Insulin Stimulated Glucose Uptake) — 4.1; 5.6; 4.7; 5.5 mg/kg.min — p=0.4
Phase 1 N=110 Safety and Efficacy of AL-53817 Nasal Spray Solution
Nasal Allergies · Allergies
Primary: Number of Adverse Events in Stage A — 9; 3; 0; 0 Adverse Events
Phase 1 N=8 Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
Phase 1 N=36 Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Crohn's Disease
Primary: Incidence of Adverse Events — 7; 4; 1; 7 events
Phase 1 N=44 Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes
Type 2 Diabetes
Primary: Number of Subjects With Study Drug-Related Adverse Events — 9; 11; 9; 11 participants
Phase 1 N=15 Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Hematologic Malignancy · Malignant Lymphoma
Primary: Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin — 911.0; 1020.7 ng*hr/mL
Phase 1 N=14 Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Hematologic Malignancy · Malignant Lymphoma
Primary: Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin — 2225.1; 3966.3 ng*hr/mL
Phase 1 N=18 Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
Heart Failure
Primary: Change in Fecal Sodium Content — 635.10; 501.95 mg — p=0.0662
Phase 1 N=16 Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) — 2059.6; 1963.1; 1799.9; 2048.5 ng/mL
Phase 1 N=15 Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers
Healthy Volunteers
Primary: Cmax (the Maximum Observed Plasma Concentration) — 1147.9 ng/mL
Phase 1 N=36 Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects
Healthy Subjects
Primary: Cmax (the Maximum Observed Plasma Concentration of Ketorolac Tromethamine) — 2128; 1948 ng/mL
Phase 1 N=50 Nicotine Lozenge Bioequivalence Study
Smoking Cessation
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t [AUC(0-t)] — 18.84; 20.71; 34.71; 33.68 nanogram (ng).hour (hr)/millilitre (mL)
Phase 1 N=80 Rotavirus Vaccine Produced by Butantan Institute
Rotavirus Infections
Primary: Number of Participants With Adverse Events. — 14; 12 participants
Phase 1 N=5 Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease
Lesch-Nyhan Disease
Primary: Number of Participants With Clinically Significant Changes in Standard Laboratory Tests — 0 Participants